Reuters Health News Summary


Reuters | Updated: 23-02-2020 02:28 IST | Created: 23-02-2020 02:28 IST
Reuters Health News Summary

Following is a summary of current health news briefs. China's Hubei province revises February 19 new cases tally to 775, from 349 previously

China's Hubei province, the epicentre of the coronavirus outbreak, on Friday revised the number of new cases it reported on Feb. 19 to 775, from 349 previously. Earlier in the day, provincial authorities said they would add back some cases to their tally of the disease, after they adjusted their methodology to count only cases that were detected with genetic tests, rather than with CT scans. World must act fast to contain coronavirus: WHO's Tedros

The window of opportunity to contain wider international spread of the epidemic of the new coronavirus disease is closing, the World Health Organization (WHO) warned on Friday, after cases were reported in Iran and Lebanon. Tedros Adhanom Ghebreyesus, WHO director-general, asked whether the outbreak is at a "tipping point" after new cases and deaths in Iran from COVID-19, and cases in Lebanon and Canada, said that he still believed the virus spread could be stopped. Sealed in: Chinese trapped at home by coronavirus feel the strain

During weeks holed up in her grandmother's apartment with 10 relatives and eating a restricted diet, Chinese teenager Li Yuxuan says tempers have frayed. Li and her family are among the millions of people across China's Hubei province, epicenter of the coronavirus outbreak, who are subject to official orders to stay at home amid attempts to contain the spread of the disease. Japan govt faces questions over coronavirus, Tokyo cancels events

Japan faced growing questions about whether it was doing enough to stop the spread of the coronavirus on Friday, as the Tokyo Metropolitan Government said it would cancel or postpone major indoor events it has sponsored for the next three weeks. More than 400 Japanese and foreign passengers were set to disembark from the virus-hit Diamond Princess cruise ship near Tokyo after weeks aboard in quarantine, despite reports of new cases coming in from around Japan. School lunch overhaul led to healthier meals for U.S. kids

An overhaul of school lunch nutrition standards seems to have driven dramatic improvements in the healthiness of meals served to millions of kids nationwide, a U.S. study suggests. The goal of new nutrition standards implemented during the 2012-2013 academic year was to bring breakfast and lunch menus in line with dietary guidelines designed to help combat obesity and other diseases linked to diets heavy in calories, sugars and fats, and light on whole foods. New coronavirus cases fall in China, but WHO concerned by global spread

China reported a sharp fall in new deaths and cases of the coronavirus on Saturday, but world health officials warned it was too early to make predictions about the outbreak as new infections continued to rise in other countries. Chinese authorities said the mainland had 397 new confirmed cases on Friday, down from 889 a day earlier. The numbers surged elsewhere, though, with outbreaks worsening in South Korea, Iran, Italy and Lebanon. U.S. prepares for coronavirus pandemic, school and business closures: health officials

U.S. health officials on Friday said they are preparing for the possibility of the spread of the new coronavirus through U.S. communities that would force closures of schools and businesses. The United States has yet to see community spread of the virus that emerged in central China in late December. But health authorities are preparing medical personnel for the risk, Nancy Messonnier, an official with the Centers for Disease Control and Prevention (CDC) told reporters on a conference call. FDA approves Lundbeck's migraine prevention therapy

The U.S. Food and Drug Administration approved Lundbeck A/S' migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday. For Lundbeck, the approval opens doors to a lucrative but competitive market dominated by already approved rivals from Amgen Inc, Teva Pharmaceutical Industries Ltd and Eli Lilly and Co. Esperion says cholesterol drug gets U.S. approval; eyes $10 per pill pricing

Esperion Therapeutics Inc said on Friday that U.S. health regulators approved its cholesterol-lowering drug, making it the first non-statin treatment to be cleared for sale in the country in nearly 20 years. The drug, bempedoic acid, to be used as an add-on treatment with statins, lowers bad cholesterol or low-density lipoprotein (LDL) by inhibiting its synthesis in the liver and is aimed at patients with high cardiovascular risk, the company said in a statement. FDA approves Eli Lilly's Trulicity to reduce cardiovascular risks in type 2 diabetic patients

Eli Lilly and Co said on Friday the U.S. Food and Drug Administration has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients. The approval makes Trulicity the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease, the company said in a statement.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback